In Vivo

China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle

US IND For First 'Made In China' Contender

24 Jan 2022

Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.

BIOFUTURE FORUM'S GENE THERAPY PANEL HELD IN SHANGHAI JAN 11-12, 2022 — BIOFUTURE FORUM'S GENE PANEL DISCUSSION HELD IN SHANGHAI, 11-12 JANUARY 2022 • Source: Brian Yang/Scrip

Founded in 2017, Belief Biomed Inc. has fast grown to become one of the front-runners in gene therapy development in China. The Shanghai-based company, backed by Qiming Venture Partners, has already obtained its first local investigative new drug clearance for a hemophilia B therapy.

Co-founded by Xiao Xiao, a former professor at the University of North Carolina in the US, Belief is just one...